38 research outputs found
A study on the heavy payloads underwater manipulator for deep-sea driven by electric motor
In this study, a development of a 6 D.O.F underwater manipulator which is actuated by electric motors capable of carrying over 70kg payload. It designed to be driven at 3,000m. Balancing weight is applied to reduce the capacity of the joint-2 actuator. I calculated the ideal motor capacity by interpreting inertia torque where is on the each joint actuator. The joint actuator for the manipulator is designed as a double oil jacket for waterproofness in high pressure. Each link is designed the modularization to assemble and replace the parts easily. The kinematics and dynamics of the manipulator has been analyzed based on new designed manipulator. By doing this, I can figured out the feature of 6-axis manipulator motion and stability evaluation of link structure. Also, Thickness of link cylinder at 3,000m has been verified through FEM simulation.1. μ λ‘
1.1 κ°μ
1.2 κΈ°μ‘΄ 맀λν°λ μ΄ν° λΆμ
1.2.1 μ μ ꡬλ λ°©μμ μμ€ λ§€λν°λ μ΄ν°
1.2.2 μ κΈ° λͺ¨ν° λ°©μμ μμ€ λ§€λν°λ μ΄ν°
1.3 μ°κ΅¬λ²μ λ° λͺ©μ
2. μμ€ λ§€λν°λ μ΄ν°μ ꡬ쑰μ€κ³
2.1 μμ€ 6μΆ λ§€λν°λ μ΄ν°μ κ΅¬μ± λ° μ€κ³μ‘°κ±΄
2.2 μμ€ 6μΆ λ§€λν°λ μ΄ν°μ κ΄μ ꡬλκΈ° μ©λμ€κ³
2.2.1 κ° κ΄μ μ κ΄μ±λͺ¨λ©νΈ κ°μ λ° ν΄μ
2.2.2 κ° κ΄μ μ κ°μλ λ° κ°κ°μλ ν΄μ
2.2.3 κ° κ΄μ μ κ΄μ±λ ₯μ μν ν ν¬ ν΄μ
2.2.4 λ§ν¬μ€λμ μν΄ λ°μνλ κ° κ΄μ μ ν ν¬ ν΄μ
2.2.5 νλ ₯μ μν΄ λ°μνλ κ° κ΄μ μ ν ν¬ ν΄μ
2.2.6 κ° κ΄μ μ κ΄μ±λ ₯κ³Ό 무κ², νλ ₯μ μν ν ν¬ ν΄μ
2.3 κ΄μ ꡬλκΈ° 기ꡬꡬ쑰 μ€κ³
2.3.1 κ΄μ ꡬλκΈ°μ μλ°κ΅¬μ‘°
2.3.2 κ΄μ ꡬλκΈ° λ°°μΉμ€κ³
2.4 μμ€ 6μΆ λ§€λν°λ μ΄ν°μ κΈ°κ΅¬λΆ μ€κ³
3. μμ€ 6μΆ λ§€λν°λ μ΄ν°μ 기ꡬν λ° λμν ν΄μ
3.1 맀λν°λ μ΄ν°μ μ기ꡬν ν΄μ
3.2 맀λν°λ μ΄ν°μ μ기ꡬν ν΄μ
3.3 맀λν°λ μ΄ν°μ μλ 기ꡬν ν΄μ
3.4 맀λν°λ μ΄ν°μ λμν ν΄μ
4. μμ€ 6μΆ λ§€λν°λ μ΄ν° λ§ν¬μ μ νμμν΄μ
4.1 맀λν°λ μ΄ν°μ λ§ν¬ μ€λ¦°λ λ΄μ ν΄μ
4.1.1 μ€λ¦°λ λͺ¨λΈλ§κ³Ό κ²½κ³μ‘°κ±΄
4.1.2 μ€λ¦°λ μλ ₯ ν΄μ κ²°κ³Ό
4.1.3 μ€λ¦°λ μ’κ΅΄ ν΄μ κ²°κ³Ό
5. κ²°λ‘
μ°Έκ³ λ¬Έ
μ·¨μ μ¬λΆμ λ°λ₯Έ κΈ°νΌμ¬μ±μ μΆκ° μΆμ°μν₯
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : κ²½μ νλΆ, 2013. 2. λ₯κ·Όκ΄.λ³Έ μ°κ΅¬λ μ°λ¦¬λλΌ κΈ°νΌμ¬μ±μ μ·¨μ
μ¬λΆμ λ°λΌ κ²½μ μ , λ¬Ένκ°μΉκ΄, μ§μμ νΉμ±μ΄ μΆκ°μΆμ°μν₯μ λ―ΈμΉλ μν₯μ μμλ³΄κ³ μ νμλ€. λΆμμ μν΄ ν΅κ³μ²μ 2005λ
μΈκ΅¬μ£Όνμ΄μ‘°μ¬ λ§μ΄ν¬λ‘λ°μ΄ν°λ₯Ό νμ©νμκ³ λ§ 20-40μΈ κΈ°νΌμ¬μ± 76,385λͺ
μ λμμΌλ‘ νμ¬ νλ‘λΉ νκ· λͺ¨νμ μ¬μ©νμλ€.
λΆμ κ²°κ³Ό, κ²½μ μ , λ¬Ένκ°μΉκ΄ λ³μλΏλ§ μλλΌ μ§μλ³ λ³μκ° μΆκ° μΆμ°μν₯μ μν₯μ λ―ΈμΉλ κ²μΌλ‘ λνλ¬λ€. μ§μλ³ μ€μ
λ₯ μ μ·¨μ
μ¬μ±κ³Ό λ―Έμ·¨μ
μ¬μ±μ μΆκ° μΆμ°μν₯μ κ°μμν€λ κ²μΌλ‘ λνλ¬μΌλ©° 보μ‘μμ€ κ³΅κΈλ₯ λ³μλ λ―Έλ―Ένμ§λ§ λ―Έμ·¨μ
μ¬μ±κ³Ό μ·¨μ
μ¬μ±μ μΆκ° μΆμ°μν₯μ λμ΄λ κ²μΌλ‘ λνλ¬λ€.
λν μ·¨μ
μ¬λΆμ λ°λΌ κ° λ
립 λ³μΈλ€μ΄ μΆκ° μΆμ°μν₯μ μμ΄νκ² μν₯μ λ―ΈμΉλ κ²μΌλ‘ λνλ¬λ€. λ―Έμ·¨μ
μ¬μ±μ κ²½μ μ νΉμ±μ λνλ΄λ λ³μμΈ λ¨νΈμ μλμ΄λ μ§μλ³ μ€μ
λ₯ λ±μμ μν₯μ λ°λ κ²μΌλ‘ λνλ¬λ€. λ°λ©΄, μ·¨μ
μ¬μ±μ κ²½μ° μκΈκ·Όλ‘ μ¬λΆμ λ°λΌ μν₯μ μ°¨μ΄λ₯Ό 보μμΌλ©°, 보μ‘μμ€ κ³΅κΈλ₯ μ΄ μΆμ°μν₯μ λ―ΈμΉλ μν₯ λν λ―Έμ·¨μ
μ¬μ±μ λΉν΄ ν° κ²μΌλ‘ λνλ μλ
μμ‘κ³Ό κ΄λ ¨λ νΉμ±μ΄ μ€μνκ² κ³ λ €λκ³ μμμ νμ
ν μ μμλ€.
κ²°λ‘ μ μΌλ‘ λ³Έ μ°κ΅¬λ μ€μ¦λΆμμ ν΅ν΄ μ¬μ±μ μ·¨μ
μ¬λΆ λ° μ§μλ³ νΉμ±μ΄ μΆμ°μν₯μ μν₯μ μ€ μ μμμ 보μλ€. μ΄λ₯Ό λ°νμΌλ‘ μΆμ°μ¨ μ κ³ λ₯Ό μν μ μ±
μ립 μ μ¬μ±μ μ·¨μ
μ¬λΆ λ° μ§μλ³ νΉμ±μ κ³ λ €ν μ°¨λ³νλ μ μ±
λ€μ΄ μ립 λ° μνλμ΄μΌ νλ€λ μ μ±
μ ν¨μλ₯Ό μ μνμλ€.μ 1 μ₯ μλ‘ 1
1-1. μ°κ΅¬ λκΈ° 1
1-2. μ°κ΅¬ μμ 3
μ 2 μ₯ μ΄λ‘ μ λ°°κ²½ λ° μ νμ°κ΅¬ 4
2-1. κ²½μ νμ μ κ·Ό 4
2-2. λ¬Ένκ°μΉκ΄ μ κ·Ό 6
2-3. μ§μμ μ κ·Ό 7
μ 3 μ₯ λ°μ΄ν° λ° κΈ°μ ν΅κ³λ 10
3-1. λΆμμλ£ 10
3-2. κΈ°μ ν΅κ³λ 11
μ 4 μ₯ μ°κ΅¬λ°©λ² λ° λ³μμ€λͺ
14
4-1. μ°κ΅¬λ°©λ² 14
4-2. λ³μμ€λͺ
16
μ 5 μ₯ λΆμκ²°κ³Ό 20
5-1. μ·¨μ
μ¬λΆμ λ°λ₯Έ μΆκ° μΆμ°μν₯ 20
5-2. κ²½μ μ Β·λ¬Ένκ°μΉκ΄ λ³μμ μν₯ λΆμ 21
5-3. λΆλͺ¨μμ λκ±°μ¬λΆμ λ¨μμ νΈμ¬μμ κ΄κ³ 26
5-4. κ²½μ μ Β·λ¬Ένκ°μΉκ΄Β·μ§μμ λ³μμ μν₯ λΆμ 27
μ 6 μ₯ κ²°λ‘ λ° ν¨μ 31Maste
Effects of Post Ischemia-Reperfusion Treatment with Trimetazidine on Renal Injury in Rats: Insights on Delayed Renal Fibrosis Progression
Even after recovery from acute kidney injury, glomeruli remain vulnerable to further injury by way of interstitial fibrosis. This study is aimed at elucidating the effects of post ischemia-reperfusion (I/R) treatment with trimetazidine on the progression to renal fibrosis as well as short- and intermediate-term aspects. Trimetazidine 3βmg/kg or 0.9% saline was given intraperitoneally once upon reperfusion or daily thereafter for 5βd or 8βw. Renal histologic changes and related signaling proteins were assessed. After 24βh, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1Ξ±, vascular endothelial growth factor (VEGF), and Bcl-2 expression. After 5βd, post I/R treatment with trimetazidine reduced renal tubular cell necrosis and apoptosis with upregulation of HIF-1Ξ±-VEGF and tissue inhibitors of metalloproteinase activities, attenuation of matrix metalloproteinase activities, and alteration of the ratio of Bax to Bcl-2 levels. After 8βw, however, post I/R treatment with trimetazidine did not modify the progression of renal fibrosis. In conclusion, post I/R treatment with trimetazidine allows ischemic kidneys to regain renal function and structure more rapidly compared to nontreated kidneys, but not enough to resolute renal fibrosis in long-term aspect.ope
Renoprotective effects of dexmedetomidine against ischemia-reperfusion injury in streptozotocin-induced diabetic rats.
BACKGROUND: Diabetic patients are susceptible to renal ischemia-reperfusion injury, which leads to perioperative complications. Activation of NOD-like receptor protein 3 (NLRP3) inflammasome participates in the development of diabetes, and contributes to renal ischemia-reperfusion injury. Dexmedetomidine (DEX), a highly selective Ξ±2-adrenoreceptor agonist, shows renoprotective effects against ischemia-reperfusion injury. We aimed to elucidate the effects, underlying mechanisms, and optimal timing of DEX treatment in diabetic rats.
METHODS: Male Sprague-Dawley rats (n = 12 per group) were randomly divided into normal-sham, diabetes-sham, diabetes-ischemia-reperfusion-control, diabetes-ischemia-reperfusion-DEX-pre-treatment, and diabetes-ischemia-reperfusion-DEX-post-treatment groups. Renal ischemia-reperfusion injury was induced in diabetic rats by occlusion of both renal arteries for 45 min, followed by reperfusion for 24 h. DEX (10 ΞΌg/kg) was administered intraperitoneally 1 h before ischemia (pre-treatment) or upon reperfusion (post-treatment). After reperfusion, renal tissue was biochemically and histopathologically evaluated.
RESULTS: DEX treatment attenuated ischemia reperfusion-induced increase in NLRP3, caspase-1, IL-1Ξ², phospho-AKT, and phospho-ERK signaling. Moreover, oxidative stress injury, inflammatory reactions, apoptosis, and renal tubular damage were favorably modulated by DEX treatment. Furthermore, post-reperfusion treatment with DEX was significantly more effective than pre-treatment in modulating NLRP3 inflammasome, AKT and ERK signaling, and oxidative stress.
CONCLUSIONS: This study shows that the protective effects of DEX in renal ischemia-reperfusion injury are preserved in diabetic conditions and may potentially provide a basis for the use of DEX in clinical treatment of renal ischemia-reperfusion injury.ope
Protective Effect of Ethyl Pyruvate against Myocardial Ischemia Reperfusion Injury through Regulations of ROS-Related NLRP3 Inflammasome Activation
Emerging evidence indicates the pronounced role of inflammasome activation linked to reactive oxygen species (ROS) in the sterile inflammatory response triggered by ischemia/reperfusion (I/R) injury. Ethyl pyruvate (EP) is an antioxidant and conveys myocardial protection against I/R injury, while the exact mechanisms remain elusive. We aimed to investigate the effect of EP on myocardial I/R injury through mechanisms related to ROS and inflammasome regulation. The rats were randomly assigned to four groups: (1) sham, (2) I/R-control (IRC), (3) EP-pretreatmentβ+βI/R, and (4) I/Rβ+βEP-posttreatment. I/R was induced by a 30βmin ligation of the left anterior descending artery followed by 4βh of reperfusion. EP (50βmg/kg) was administered intraperitoneally at 1βh before ischemia (pretreatment) or upon reperfusion (posttreatment). Both pre- and post-EP treatment resulted in significant reductions in myocardial infarct size (by 34% and 31%, respectively) and neutrophil infiltration. I/R-induced myocardial expressions of NADPH oxidase-4, carnitine palmitoyltransferase 1A, and thioredoxin-interacting protein (TXNIP) were mitigated by EP. EP treatment was associated with diminished inflammasome activation (NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like protein, and caspase-1) and interleukin-1Ξ² induced by I/R. I/R-induced phosphorylation of ERK and p38 were also mitigated with EP treatments. In H9c2 cells, hypoxia-induced TXNIP and NLRP3 expressions were inhibited by EP and to a lesser degree by U0126 (MEK inhibitor) and SB203580 (p38 inhibitor) as well. EP's downstream protective mechanisms in myocardial I/R injury would include mitigation of ROS-mediated NLRP3 inflammasome upregulation and its associated pathways, partly via inhibition of hypoxia-induced phosphorylation of ERK and p38.ope
Effect of pregabalin administration upon reperfusion in a rat model of hyperglycemic stroke: Mechanistic insights associated with high-mobility group box 1
Hyperglycemia, which reduces the efficacy of treatments and worsens clinical outcomes, is common in stroke. Ability of pregabalin to reduce neuroexcitotoxicity may provide protection against stroke, even under hyperglycemia. We investigated its protective effect against hyperglycemic stroke and its possible molecular mechanisms. Male Wistar rats administered dextrose to cause hyperglycemia, underwent middle cerebral artery occlusion for 1 h and subsequent reperfusion. Rats were treated with an intraperitoneal injection of 30 mg/kg pregabalin or an equal amount of normal saline at the onset of reperfusion (n = 16 per group). At 24 h after reperfusion, neurological deficit, infarct volume, and apoptotic cell count were assessed. Western blot analysis was performed to determine protein expression of high-mobility group box 1 (HMGB1), toll-like receptor-4 (TLR-4), phosphorylated nuclear factor-kappa B (p-NF-ΞΊB), interleukin-1beta (IL-1Ξ²), tumor necrosis factor-alpha (TNF-Ξ±), phosphorylated inducible and endothelial nitric oxide synthase (p-iNOS, p-eNOS), Bcl-2, Bax, Cytochrome C, and caspase-3 in the brain. Pregabalin-treated rats showed significantly improved neurological function (31% decrease in score), reduced infarct size (by 33%), fewer apoptotic cells (by 63%), and lower expression levels of HMGB1, TLR4, p-NF-ΞΊB, IL-1Ξ², and TNF- Ξ±, compared with control rats. Decreased p-iNOS and increased p-eNOS expressions were also observed. Expression of Bax, Cytochrome C, and cleaved caspase-3/caspase3 was significantly downregulated, while Bcl-2 expression was increased by pregabalin treatment. Pregabalin administration upon reperfusion decreased neuronal death and improved neurological function in hyperglycemic stroke rats. Cogent mechanisms would include attenuation of HMGB1/TLR-4-mediated inflammation and favorable modulation of the NOS.ope
Effects of propofol on the expression of matric metalloproteinases in rat cardiac fibroblasts after hypoxia and reoxygenation.
BACKGROUND: Propofol is known to protect the myocardium against ischaemia/reperfusion (I/R) injury through its antioxidant and anti-inflammatory properties. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cell migration and invasion, and mediate tissue remodelling during I/R injury. They are regulated by various mechanisms including oxidative stress and AKT and ERK pathways. We investigated whether propofol affected the expression of MMPs and subsequent cell migration and invasion and the signalling pathways involved in primary rat cardiac fibroblasts undergoing hypoxia and reoxygenation.
METHODS: The phosphorylation of ERK and AKT signalling pathways was examined by western blot analysis in rat primary cardiac fibroblasts after hypoxia and reoxygenation. mRNA expression of MMP and TIMPS was analysed by real-time PCR, and proteolytic activities of MMP-2 and -9 were assessed. The effects of propofol on migration, invasion, wound healing, and cell proliferation activity were evaluated after reoxygenation.
RESULTS: Propofol induced AKT and ERK1/2 activation. Subsequent activation of MMPs resulted in increased cell migration, invasion, and wound-healing activity under hypoxia-reoxygenation, which was decreased by LY294002 (AKT inhibitor) and U0126 (ERK inhibitor) in rat cardiac fibroblasts. However, propofol had no effect on proliferation or viability of cardiac fibroblasts after hypoxia-reoxygenation.
CONCLUSIONS: Propofol affected the expression of MMPs and TIMPs and subsequently induced cell migration and invasive ability, through activation of the ERK and AKT signalling pathway in hypoxia-reoxygenated rat cardiac fibroblastsope
A study on the Prevalence and Related Factors of Post-Intensive Care Syndrome(PICS) of Intensive Care Survivors
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : κ°νΈνκ³Ό, 2017. 2. κ°μΉμ.μ§μ€μΉλ£ ν μ¦νκ΅°(Post Intensive Care Syndrome: PICS)'μ μ€μ¦ μ§νμ΄λ κΈμ± μ
μ μΉλ£ ν λνλλ 볡ν©μ μΈ μ¦μμΌλ‘μ μ΄μ λ³΄λ€ μ
νλκ±°λ μλ‘ μ겨λ κ±΄κ° λ¬Έμ λ‘ ν¬κ² μ 체μ , μΈμ§μ , μ μ μ μ¦μμΌλ‘ λλλ€.
λ³Έ μ°κ΅¬λ μ€νμ μμ‘΄μμ μ§μ€μΉλ£ ν μ¦νκ΅°μ μ€νμ κ΄λ ¨μμΈμ νμ
νκΈ° μν μμ μ μκ΄κ΄κ³ μ°κ΅¬μ΄λ€. μ°κ΅¬μ λͺ©μ μ μ€νμκ΄λ ¨ μλ£μ§ λ° κ±΄κ°κ΄λ ¨ μ’
μ¬μ, μ€νμ μμ‘΄μμκ² μ§μ€μΉλ£ ν μ¦νκ΅°μ λν΄ μΈμνκ² νκ³ μλ°©κ³Ό μΉλ£μ μ€μμ±μ μλ € μ€νμμ€ μμ‘΄μμ μΆμ μ§μ μν΄ μ₯κΈ°μ μΌλ‘ κ΄λ¦¬ν μ μλ μ λλ₯Ό λ§λ ¨νλ κ²μ΄λ€.
μλ£ μμ§μ 2016λ
8μ 1μΌλΆν° 9μ 30μΌκΉμ§ μμΈ μλ΄ μΌκ° λνλ³μμ νμ 104λͺ
μ λμμΌλ‘ μννμλ€. μ§μ€μΉλ£ ν μ¦νκ΅° μΈ‘μ μ μν΄ μ 체μ κΈ°λ₯(K-ADL), μΈμ§μ κΈ°λ₯(MMSE-K), μ μ μ κΈ°λ₯(HADS, IES-R-K)μ ꡬ쑰νλ μ€λ¬Έμ§κ° μ¬μ©λμλ€. μλ£λ κΈ°μ ν΅κ³, t-test, one-way ANOVA, Pearsons correlation coefficient, Multiple regression λ°©λ²μ μ΄μ©νμ¬ λΆμνμλ€.
μ°κ΅¬ κ²°κ³Όλ λ€μκ³Ό κ°λ€.
1. μ€νμ μμ‘΄μ μ€ 89λͺ
(85.6%)μ΄ μ§μ€μΉλ£ ν μ¦νκ΅°μ ν΄λΉνμκ³ , μ΄λ€μ λ³Έ μ°κ΅¬μμ μΈ‘μ ν 5κ°μ μ¦μ μ€ νκ· 2κ°μ μ¦μμ κ²½ν νλ κ²μΌλ‘ λνλ¬λ€. λν PICS μ¦μ μ€ μΈμ§μ Β· μ 체μ λ¬Έμ μ λΉν΄ μ μ μ λ¬Έμ (λΆμ, μ°μΈ, PTSD)κ° λ§μ΄ λ°μνμλ€.
2. K-ADLλ‘ μΈ‘μ ν μ 체기λ₯μ₯μ κ° μλ λμμλ 28λͺ
(26.9%), MMSE-Kλ‘ μΈ‘μ ν μΈμ§κΈ°λ₯μ₯μ κ° μμ¬λκ±°λ μΈμ§κΈ°λ₯μ₯μ κ° μλ λμμλ 30λͺ
(28.9%)μ΄μλ€. HADSλ‘ μΈ‘μ ν λΆμ μ¦μμ νΈμνλ λμμλ μ΄ 36λͺ
(34.7%), μ°μΈ μ¦μμ νΈμνλ λμμλ μ΄ 75λͺ
(72.1%)μ΄μλ€. IES-R-Kλ‘ μΈ‘μ ν PTSDλ₯Ό νΈ μνλ λμμλ μ΄ 38λͺ
(36.5%)μ΄μλ€.
3. μ 체μ Β· μΈμ§μ Β· μ μ μ μ¦μμ μ μν μ°¨μ΄κ° μλ κ²μΌλ‘ λνλ λμμμ μ§λ³ νΉμ±μ λ€μκ³Ό κ°λ€. μΌμμνκΈ°λ₯μ ν¨νμ¦ (p=.047), μ€νμμ€ μ¬μ μΌμ(p=.020), μΉμμ (p=.031)μμ, μΈμ§κΈ°λ₯μ μ§λ³μ€μ¦λ(p<.001), μ€νμμ€ μ
Β· ν΄μ€ μ μμμμ€(p=.045, p<.001)μμ, λΆμμ ν¨νμ¦(p=.042), μ°μΈμ μ§μμ μΈμλ¦°(p=.002),μ€ν
λ‘μ΄λ μΉλ£(p=.004), PTSDλ μ€νμμ€ μ
μ€ νμ(p=.012)μμ μ μν μ°¨μ΄λ₯Ό 보μλ€.
4. PICSμ μν₯μ λ―ΈμΉλ μμΈμ μ€ν
λ‘μ΄λ μΉλ£(p<.001), μ§λ³μ€μ¦λ(p=.010), μ±λ³(p=.011), μ§μμ μΈμλ¦° μΉλ£(p=.022)μμΌλ©° μ΄ λ³μλ€μ PICSλ₯Ό 33.7% μ€λͺ
νμλ€.
λ³Έ μ°κ΅¬μμ μ€ν
λ‘μ΄λμ μ§μμ μΈμλ¦° μΉλ£λ PICSμ μ¦μμ κ°μμν€λ μμΈμΌλ‘ λνλ¬λ€. λν μ€μ¦λκ° λμμλ‘, λ¨μλ³΄λ€ μ¬μκ° PICSμ μ¦μμ λ λ§μ΄ κ²½ννλ κ²μΌλ‘ λνλ¬λ€. κ΅λ΄μμλ PICSμ μ€νλ₯Ό νμ
ν μ°κ΅¬κ° λλ¬ΌκΈ°μ μ§μμ¬ν, λ³μ, κ°μ λ± λ€μν νκ²½μ μλ μ€νμ μμ‘΄μλ₯Ό λμμΌλ‘ λ°λ³΅ μ°κ΅¬κ° νμνλ€. λν μ€νμ μλ£μ§μ μ€νμ μμ‘΄μκ° λ λμ μΆμ μ§μ μμν μ μλλ‘ PICSμ μν₯μ λ―ΈμΉλ κ΄λ ¨ μμΈμ νμ
νμ¬ PICSμ λ°μμ μ€μΌ μ μλλ‘ λ
Έλ ₯ν΄μΌ ν κ²μ΄λ€.
μ£Όμμ΄: μ€νμμ€, μ€νμ μμ‘΄μ, μ§μ€μΉλ£ ν μ¦νκ΅°
ν λ²: 2015-20552I. μλ‘ 1
1. μ°κ΅¬ νμμ± 1
2. μ°κ΅¬ λͺ©μ 4
3. μ©μ΄ μ μ 4
II. λ¬Ένκ³ μ°° 6
1. μ€νμμ€ νμμ κ²½ν 6
2. μ§μ€μΉλ£ ν μ¦νκ΅° 9
III. μ°κ΅¬μ μ΄λ‘ μ κΈ°ν 18
1. λμ΄ν
κ²μΌ νκ²½μ΄λ‘ 18
2. λ³Έ μ°κ΅¬μ μ΄λ‘ μ κΈ°ν 19
IV. μ°κ΅¬ λ°©λ² 21
1. μ°κ΅¬ μ€κ³ 21
2. μ°κ΅¬ λμ λ° κΈ°κ° 21
3. μ°κ΅¬ λꡬ 22
4. μλ£ μμ§ λ°©λ² λ° μ μ°¨ 26
5. μλ£ λΆμ λ°©λ² 26
6. μ€λ¦¬μ κ³ λ € 27
7. μ°κ΅¬μ μ νμ 28
V. μ°κ΅¬κ²°κ³Ό 29
1. λμμ νΉμ± 29
2. μ§μ€μΉλ£ ν μ¦νκ΅° 40
3. μ§λ³ νΉμ±μ λ°λ₯Έ μΌμμνκΈ°λ₯, λΆμ, μ°μΈ, PTSD, μΈμ§κΈ°λ₯ 43
4. λμμ νΉμ±μ λ°λ₯Έ μ§μ€μΉλ£ ν μ¦νκ΅° 48
5. μ§μ€μΉλ£ ν μ¦νκ΅° μ¦μ κ°μ μκ΄κ΄κ³ 55
6. μ§μ€μΉλ£ ν μ¦νκ΅°μ μν₯μ λ―ΈμΉλ μμΈ 57
VI. λ
Ό μ 59
1. μ§μ€μΉλ£ ν μ¦νκ΅°μ μ€ν 59
2. μ§μ€μΉλ£ ν μ¦νκ΅°μ κ΄λ ¨μμΈ 62
VII. κ²°λ‘ λ° μ μΈ 66
1. κ²° λ‘ 66
2. μ μΈ 68
μ°Έκ³ λ¬Έν 69
λΆ λ‘ 81
Abstract 92Maste
쑰골μΈν¬ λΆνμμ ERK 12 ν΅ν Runx2 μμ μ± μ‘°μ μ κ΄ν μ°κ΅¬
Thesis(doctors) --μμΈλνκ΅ λνμ :μΉμνκ³Ό(λκ°μ
μλ©΄ μΈν¬ λ° λ°μμλ¬Όνμ 곡),2008. 8.Docto
Nano-fibrous scaffolding promotes osteoblast differentiation and biomineralization
Nano-fibrous poly(l-lactic acid) (PLLA) scaffolds with interconnected pores were developed under the hypothesis that nano-fibrous scaffolding would mimic a morphological function of collagen fibrils to create a more favorable microenvironment for cells versus solid-walled scaffolds. In this study, an in vitro system was used to examine biological properties of the nano-fibrous scaffolds compared with those of solid-walled scaffolds for their potential use in bone tissue engineering. Biomineralization was enhanced substantially on the nano-fibous scaffolds compared to solid-walled scaffolds, and this was confirmed by von Kossa staining, measurement of calcium contents, and transmission electron microscopy. In support of this finding, osteoblasts cultured on the nano-fibrous scaffolds exhibited higher alkaline phosphatase activity and an earlier and enhanced expression of the osteoblast phenotype versus solid-walled scaffolds. Most notable were the increases in runx2 protein and in bone sialoprotein mRNA in cells cultured on nano-fibrous scaffolds versus solid-walled scaffolds. At the day 1 of culture, Ξ±2 and Ξ²1 integrins as well as Ξ±v and Ξ²3 integrins were highly expressed on the surface of cells seeded on nano-fibrous scaffolds, and linked to this were higher levels of phospho-Paxillin and phospho-FAK in cell lysates. In contrast, cells seeded on solid-walled scaffolds expressed significantly lower levels of these integrins, phospho-Paxillin, and phospho-FAK. To further examine the role of nano-fibrous architecture, we inhibited the formation of collagen fibrils by adding 3,4-dehydroproline to cultures and then assayed cells for expression of Ξ±2 integrin. Cells seeded on nano-fibrous scaffolds sustained expression of Ξ±2 integrin in the presence of dehydroproline, while suppression of Ξ±2 integrin was evident in cells seeded on solid-walled scaffolds. These results provide initial evidence that synthetic nano fibers may exhibit certain properties that are comparable to natural collagen fibers, and thus, the nano-fibrous architecture may serve as a superior scaffolding versus solid-walled architecture for promoting osteoblast differentiation and biomineralization.ope